Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Certification to Enable Development of MDx-related Software

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Atlas Biolabs today said that it has achieved DIN EN ISO 13485:2003 + AC:2009 standard, allowing the company to develop a software-based expert system for assessing chromosomal aberrations.

The system will complement Atlas' genotyping and molecular karyotyping services.

According to the company, the certification is a milestone for Atlas and compliance is necessary to develop and distribute software that falls within the scope of the European directive 98/79/EC for in vitro diagnostics.

"The new certificate gives the company a stronger position in molecular diagnostics and makes it an ideal partner for other companies that are looking to develop or have developed in vitro diagnostic tools," Atlas said in a statement.

The company had been certified according to DIN EN ISO 9001 since 2008.

Based in Berlin, Atlas provides genomics services, such as microarray-based genomic services, targeted sequence capture, and next-generation sequencing analysis.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.